<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04308811</url>
  </required_header>
  <id_info>
    <org_study_id>ASU456</org_study_id>
    <nct_id>NCT04308811</nct_id>
  </id_info>
  <brief_title>Autologous Platelet-Rich Plasma in the Management of Asherman Syndrome</brief_title>
  <official_title>Platelet-Rich Plasma in the Management of Asherman Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to find out the benefit of the platelet-rich plasma in preventing
      reformation of intrauterine adhesions after adhesiolysis in cases of Asherman syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients fulfilling criteria will be randomized into three equal groups. The patients who are
      diagnosed previously with severe AS will choose an envelope which determines the treatment
      method. There will be 60 envelops assigning for the groups mixed together in one box. This
      will ensure a randomized allocation of patients to either group of this study.

      Hysteroscopy adhesiolysis will be done to all participants in the study. in the first group,
      Adhesiolysis will be followed by intrauterine use of PRP then insertion of intrauterine Foley
      balloon catheter that will be inflated and left for 2 weeks. in the second group,
      adhesiolysis will be followed by insertion of intrauterine Foley balloon catheter covered by
      freeze-dried amniotic graft and will be inflated and left for 2 weeks. In the third group,
      Adhesiolysis will be followed by insertion of intrauterine Foley balloon catheter that will
      be inflated and left for 2 weeks. All patients will be given antibiotics and hormonal
      treatment. Also, they will be given low dose aspirin and sildenafil 50mg daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2019</start_date>
  <completion_date type="Actual">February 20, 2020</completion_date>
  <primary_completion_date type="Actual">February 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The patients who are diagnosed previously with severe AS will choose an envelope which determines the treatment method. There will be 60 envelops assigning for the groups mixed together in one box. This will ensure a randomized allocation of patients to either group of this study. Hysteroscopy adhesiolysis will be done to all participants in the study. in the first group, Adhesiolysis will be followed by intrauterine use of PRP then insertion of Foley balloon catheter. in the second group, adhesiolysis will be followed by insertion of Foley balloon catheter covered by freeze-dried amniotic graft. In the third group, Adhesiolysis will be followed by insertion of Foley balloon catheter. All foley ballon removed 2 weeks postoperative. All patients will be given antibiotics and hormonal treatment. Also, they will be given low dose aspirin and sildenafil 50mg daily.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade of intrauterine adhesions</measure>
    <time_frame>after one month</time_frame>
    <description>Grade of intrauterine adhesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>menstruation</measure>
    <time_frame>within three months postoperative</time_frame>
    <description>amount of menstrual blood change</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Intrauterine Adhesion</condition>
  <arm_group>
    <arm_group_label>platelet rich plasma group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>intrauterine platelet rich plasma injection and intrauterine balloon insertion after hysteroscopic lysis of intrauterine adhesions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amniotic membrane graft group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>the clinician will perform hysteroscopic lysis of intrauterine adhesions followed by application of intrauterine balloon covered by freeze-dried amniotic membranes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intrauterine balloon group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>the clinician will perform hysteroscopic lysis of intrauterine adhesions followed by application of intrauterine balloon</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>platelet rich plasma</intervention_name>
    <description>Platelet rich plasma and intrauterine balloon applied intrauterine after hysteroscopic adhesiolysis of intrauterine adhesions</description>
    <arm_group_label>platelet rich plasma group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>amniotic membrane graft group</intervention_name>
    <description>amniotic membrane applied on the intrauterine balloon after hysteroscopic lysis of intrauterine adhesions</description>
    <arm_group_label>amniotic membrane graft group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intrauterine balloon</intervention_name>
    <description>intrauterine balloon applied intrauterine after hysteroscopic lysis of intrauterine adhesions</description>
    <arm_group_label>intrauterine balloon group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Severe intrauterine synechia confirmed by hysteroscopy

          -  age group from 20 to 40 years

        Exclusion Criteria:

          -  Hemoglobin less than 11 g/dl

          -  Platelet less than 150000/mm3

          -  Patients taking anticoagulants

          -  Patients taking NSAID in the 15 days prior to the procedure

          -  Active cervical or uterine infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Endoscopy unit, Ain shams university Maternity hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed I Amer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gynatresia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

